Biologic markers in osteology: Current state;Biomarker in der osteologie: Aktueller stand

Journal fur Mineralstoffwechsel

Volumn 13, Issue 3, 2006, Pages 82-87

  Bieglmayer, Ch ^a   Clodi, M ^a   Kudlacek, St ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PYRIDINOLINE;

BONE DENSITOMETRY; BONE DISEASE; BONE TURNOVER; HUMAN; LABORATORY TEST; OSSIFICATION; OSTEOLYSIS; REVIEW; SEX DIFFERENCE;

EID: 33748935326     PISSN: 10237763     EISSN: 16809408     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. The Working Group for Formulating Clinical Management Guidelines for Osteoporosis in Hong Kong. Clinical management guidelines for osteoporosis in Hong Kong. HKMJ 1998; 4: 423-31.
2. National Institute of Health. Osteoporosis prevention, diagnosis, therapy. NIH Consenus Statement 2000; 17: 1-45.
3. Osteoporosis clinical guidelines for prevention and treatment- update on pharmacological interventions and an algorithm for management. Royal College of Physicians, Bone and Tooth Society of Great Britain. 2000, http://www.rcplondon. ac.uk/pubs/wp_osteo_update.htm
4. Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M. Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 2001; 19: 338-44.
5. North American Menopause Society. Management of postmenopausal osteoporosis: position statement. Menopause 2002; 9: 84-101.
6. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl): S1-S34.
7. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Jofinston Jr. CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544-64.
8. Nelson HD, Morris CD, Kraemer DF. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evidence Report/Technology Assessment No. 28. AHRQ Publication No. 01-E032. Agency for Healthcare Research and Quality, Rockville, MD. January 2001, 1-13. www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter. 39885
9. Management of osteoporosis. 71 A national clinical guideline. Scottish Intercollegiate Guidelines Network 2003.
10. Arzneiverordnung in der Praxis. Osteoporose. Therapieempfehlungen der Arzneimittelkommission der Deutschen Ärzteschaft 2003.
11. Institute for Clinical Systems Improvement. Diagnosis and treatment of osteoprosis. National Guideline Clearinghouse, 2003, www.guideline.gov
12. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. National Guideline Clearinghouse, 2003, www.guideline.gov
13. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-57.
14. Pfeilschifter J. DVO Leitlinie zur Propylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr, Endversion der Langfassung, April 2006; 1-401. www.lutherhaus.de/ osteo/leitlinien-dvo/aktualisierung/Langfassung% 20DVO%20Leitlinie%2011-05-06. pdf
15. Pfeilschifter J. DVO Leitlinie zur Propylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr, Endversion der Kurzfassung, April 2006; 1-26. www.lutherhaus.de/ osteo/leitlinien-dvo/aktualisierung/Kurzfassung% 20DVO%20Leitlinie%2011-05-06. pdf
16. Raspe H. DVO Leitlinie zur Prophylaxe, Diagnostik und Therapie der glukokortikoidinduzierten Osteoporose, Erstversion Mai 2006; 1-86. http://www.lutherhaus.de/osteo/leitlinien-dvo/aktualisierung/DVOgluco.pdf
17. Deutsches Netzwerk der Bone and Joint Decade (BJD), International Osteoporosis Foundation, Berufsverband der Fachärzte für Orthopädie (BVO), Dachverband der deutschsprachigen wissenschaftlichen Gesellschaften für Osteologie (DVO), Deutsche Gesellschaft für Unfallchirurgie (DGU), Bundesselbsthilfeverband für Osteoporose, Deutsche Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC), Kuratorium Knochengesundheit der Orthopädischen Gesellschaft für Osteologie (OGO). Weißbuch Osteoporose. Empfehlungen zur Diagnostik und Therapie der Osteoporose zur Vermeidung osteoporotischer Folgefrakturen. Hrsg. Berufsverband der Fachärzte für Orthopädie (BVO), 2004.
18. Initiative Arznei und Vernunft. Osteoporose. Hrsg. Verband der pharmazeutischen Industrie Österreichs und Hauptverband der Österreichischen Sozialversicherungsträger, 2005.
19. Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; NCCLS 2005; Guideline C 48-A, www.clsi.org
20. Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrnleitner-Pammer A, Berghold A, Goessler W, Stepan V, Dobnig H, Leb G, Renner W. Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone Min Res 2004; 19: 42-7.
21. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin N Am 2003; 32: 83-113.
22. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; 11 (Suppl 6): S2-17.
23. Tsai K-S, Jang M-H, Hsu SH-J, Cheng W-C, Chang M-W. Bone alkaline phospatase isoenzyme and carboxy terminal propeptide of Type-I procollagen in healthy Chinese girls and boys. Clin Chem 1999; 45: 136-9:
24. Gomez Jr. B, Ardakani S, Ju J, Jenkins D, Cereli MJ, Daniloff GY, Gung VT. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995; 41: 1560-6.
25. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to Alendronate therapy in elderly women. J Clin Endocr Metab 2000; 85: 3537-40.
26. Ganero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J Bone Min Res 2002; 17: 826-33.
27. Robins SP. Collagen turnover in bone diseases. Curr Opin Clin Nutr Metab Care 2003; 6: 65-71.
28. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004; 34: 187-94.
29. Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H. Markers of bone resorption - measurement in serum, plasma or urine? Clin Lab 2003; 49: 203-7.
30. Woitge HW, Pecherstorfer M, Li Y, Keck A-V, Horn E, Ziegler R, Seibel MJ. Novel serum and urine markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Min Res 1999; 14: 792-801.
31. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian Variation in the serum concentration of C-terminal telopeptide of type 1 collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31: 57-61.
32. Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002; 30: 307-13.
33. Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Ganero P, Delmas PD, Lawaetz H, Cummings SR. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J Bone Min Res 1999; 14: 1404-10.
34. Chapurlat RD, Ganero P, Bréart G, Meunier PJ, Delmas PD. Serum Type 1 collagen breakdown product (serum CTx) predicts rip fracture risk in elderly women: The EPIDOS study. Bone 2000; 27: 283-6.
35. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Äkesson K, Obrant KJ. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Min Res 2004; 19: 386-93.
36. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 2003; 9: 10-5.
37. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not? J Endocrinol Invest 2003; 26: 464-71.
38. Woitge HW, Knothe A, Witte K, Schmids-Gayk H, Ziegler R, Lemmer B, Seibel MJ. Circannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: A prospective study. J Bone Min Res 2004; 15: 2443-50.
39. Pasco JA, Henry MJ, Kotowicz MA, Sanders KM, Seeman E, Pasco JR, Schneider HG, Nicholson GC. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: The Geelong osteoporosis study. J Bone Min Res 2004; 19: 752-8.
40. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: A randomized controlled open-label prospective trial. J Bone Min Res 2004; 19: 1221-30.
41. Christiansen C, Tankó LB, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteopor Int 2003; 14: 609-13.
42. Delmas PD, Hardy P, Garnero P, Dain M. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000; 26: 553-60.
43. Hamwi A, Ganem A-H, Grebe C, Kerschan-Schindl K, Preisinger E, Boschitsch E, Bieglmayer C. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy. Clin Chem Lab Med 2001; 39: 414-7.
44. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to Alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Min Res 1998; 13: 1431-8.
45. Reginster J-Y, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J. Reduction in PINP, a marker of bone metabolism, with Raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34: 344-51.
46. Raisz L, Smith J-A, Trahiotis M, Fall P, Shoukri K, DiGennaro J, Sacco-Gibson N. Short-term Risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover. Osteoporos Int 2000; 11: 615-20.
47. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to Alendronate therapy. Osteporos Int 2000; 11: 295-303.
48. Coleman RE. The Clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94: 2521-33.
49. Ganero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 27: 187-92.
50. Brown JE, Thomson CS, Ellis SP, Gutcherl SA, Purohitr OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89: 2031-7.
51. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, Leoning SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783-91.
52. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005; 10: 504-17.
53. Fraser WD, Anderson M, Chester C, Durham B, Ahmad AM, Chattington P, Vora J, Squire C, Diver MJ. Circardian rhythm studies of serum bone resorption markers: implications for optimal sample timing and clinical utility. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (ed). Bone Markers, Biochemical and Clinical Perspectives. Martin Dunitz Ltd., 2001; 107-18.
54. Kudlacek S, Schneider B, Peterlik M, Leb G, Klaushofer K, Weber K, Woloszczuk, Willvonseder R. Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest 2003; 33: 323-31.
55. Minisola S, Dionisi S, Pacitti MT, Paglia F, Carnevale V, Scillitani A, Mazzaferro S, De Geronimo S, Pepe J, D'Erasmo E, Romagnoli E. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 2002; 13: 171-5.
56. Szulc P, Ganero P, Munoz F, Marchand F, Delmas PD. Crosssectional evaluation of bone metabolism in men. J Bone Min Res 2001; 16: 826-33.
57. Henry YM, Eastell R. Biochemical markers of bone turnover: age, gender and race as sources of biological variability. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (ed). Bone markers, biochemical and clinical perspectives. Martin Dunitz Ltd., 2001; 95-106.